231 related articles for article (PubMed ID: 31676322)
1. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.
Sperr WR; Kundi M; Alvarez-Twose I; van Anrooij B; Oude Elberink JNG; Gorska A; Niedoszytko M; Gleixner KV; Hadzijusufovic E; Zanotti R; Bonadonna P; Bonifacio M; Perkins C; Illerhaus A; Elena C; Merante S; Shoumariyeh K; von Bubnoff N; Parente R; Jawhar M; Belloni Fortina A; Caroppo F; Brockow K; Zink A; Fuchs D; Kilbertus AJ; Yavuz AS; Doubek M; Hägglund H; Panse J; Sabato V; Bretterklieber A; Niederwieser D; Breynaert C; Hartmann K; Triggiani M; Nedoszytko B; Reiter A; Orfao A; Hermine O; Gotlib J; Arock M; Kluin-Nelemans HC; Valent P
Lancet Haematol; 2019 Dec; 6(12):e638-e649. PubMed ID: 31676322
[TBL] [Abstract][Full Text] [Related]
2. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Zanotti R; Perkins C; Jawhar M; Sperr WR; Shoumariyeh K; Schwaab J; Greiner G; Henriques A; Caldas C; Fernández-Giménez C; Sánchez-Muñoz L; Mayado A; Pérez-Pons A; Schmitt-Graeff A; Duyster J; Tanasi I; Olivieri F; Mora-Casterá E; Luna I; Senent L; Bañas MH; Nuñez-García A; Jurado-Chacón M; Martín-Sánchez G; Colado E; Xicoy B; Gener-Ricós G; Gotlib J; Bonadonna P; Reiter A; Valent P; García-Montero AC; Orfao A
Lancet Haematol; 2021 Mar; 8(3):e194-e204. PubMed ID: 33508247
[TBL] [Abstract][Full Text] [Related]
3. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.
Valent P; Oude Elberink JNG; Gorska A; Lange M; Zanotti R; van Anrooij B; Bonifacio M; Bonadonna P; Gleixner KV; Hadzijusufovic E; Perkins C; Hartmann K; Illerhaus A; Merante S; Elena C; Shoumariyeh K; von Bubnoff N; Parente R; Triggiani M; Schwaab J; Jawhar M; Caroppo F; Fortina AB; Brockow K; David Fuchs ; Greul R; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Sabato V; Aberer E; Al-Ali HK; Morren MA; Varkonyi J; Zink A; Niedoszytko M; Niederwieser D; Malcovati L; Reiter A; Kennedy V; Gotlib J; Lortholary O; Hermine O; Arock M; Kluin-Nelemans H; Sperr WR;
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):81-87. PubMed ID: 30416055
[TBL] [Abstract][Full Text] [Related]
4. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.
Jawhar M; Schwaab J; Álvarez-Twose I; Shoumariyeh K; Naumann N; Lübke J; Perkins C; Muñoz-González JI; Meggendorfer M; Kennedy V; Metzgeroth G; Fabarius A; Pfeifer D; Sotlar K; Horny HP; von Bubnoff N; Haferlach T; Cross NCP; Hofmann WK; Sperr WR; García-Montero AC; Valent P; Gotlib J; Orfao A; Reiter A
J Clin Oncol; 2019 Nov; 37(31):2846-2856. PubMed ID: 31509472
[TBL] [Abstract][Full Text] [Related]
5. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.
Pardanani A; Shah S; Mannelli F; Elala YC; Guglielmelli P; Lasho TL; Patnaik MM; Gangat N; Ketterling RP; Reichard KK; Hanson CA; Vannucchi AM; Tefferi A
Blood Adv; 2018 Nov; 2(21):2964-2972. PubMed ID: 30413432
[TBL] [Abstract][Full Text] [Related]
6. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
7. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
9. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.
Pardanani A; Lasho T; Elala Y; Wassie E; Finke C; Reichard KK; Chen D; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2016 Sep; 91(9):888-93. PubMed ID: 27214377
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
Efficace F; Gaidano G; Breccia M; Voso MT; Cottone F; Angelucci E; Caocci G; Stauder R; Selleslag D; Sprangers M; Platzbecker U; Ricco A; Sanpaolo G; Beyne-Rauzy O; Buccisano F; Palumbo GA; Bowen D; Nguyen K; Niscola P; Vignetti M; Mandelli F
Lancet Oncol; 2015 Nov; 16(15):1506-1514. PubMed ID: 26404501
[TBL] [Abstract][Full Text] [Related]
12. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.
Lübke J; Naumann N; Metzgeroth G; Kreil S; Brand T; Horny HP; Sotlar K; Cross NCP; Fabarius A; Valent P; Hofmann WK; Reiter A; Schwaab J
Ann Hematol; 2023 Aug; 102(8):2077-2085. PubMed ID: 37012462
[TBL] [Abstract][Full Text] [Related]
13. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.
Kluin-Nelemans HC; Reiter A; Illerhaus A; van Anrooij B; Hartmann K; Span LFR; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Parente R; Triggiani M; Schwaab J; Jawhar M; Caroppo F; Fortina AB; Brockow K; Zink A; Fuchs D; Kilbertus A; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Sabato V; Aberer E; Niederwieser D; Breynaert C; Várkonyi J; Kennedy V; Lortholary O; Jakob T; Hermine O; Rossignol J; Arock M; Gotlib J; Valent P; Sperr WR
Leukemia; 2020 Apr; 34(4):1090-1101. PubMed ID: 31740811
[TBL] [Abstract][Full Text] [Related]
15. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
16. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
Valcárcel D; Sanz G; Ortega M; Nomdedeu B; Luño E; Diez-Campelo M; Ardanaz MT; Pedro C; Montoro J; Collado R; Andreu R; Marco V; Cedena MT; de Paz R; Tormo M; Xicoy B; Ramos F; Bargay J; Gonzalez B; Brunet S; Muñoz JA; Gomez V; Bailén A; Sanchez J; Merchán B; del Cañizo C; Vallespí T;
Lancet Haematol; 2015 Jun; 2(6):e260-6. PubMed ID: 26688236
[TBL] [Abstract][Full Text] [Related]
17. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
Marina NM; Smeland S; Bielack SS; Bernstein M; Jovic G; Krailo MD; Hook JM; Arndt C; van den Berg H; Brennan B; Brichard B; Brown KLB; Butterfass-Bahloul T; Calaminus G; Daldrup-Link HE; Eriksson M; Gebhardt MC; Gelderblom H; Gerss J; Goldsby R; Goorin A; Gorlick R; Grier HE; Hale JP; Hall KS; Hardes J; Hawkins DS; Helmke K; Hogendoorn PCW; Isakoff MS; Janeway KA; Jürgens H; Kager L; Kühne T; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Meyers PA; Mottl H; Nathrath M; Papai Z; Randall RL; Reichardt P; Renard M; Safwat AA; Schwartz CL; Stevens MCG; Strauss SJ; Teot L; Werner M; Sydes MR; Whelan JS
Lancet Oncol; 2016 Oct; 17(10):1396-1408. PubMed ID: 27569442
[TBL] [Abstract][Full Text] [Related]
18. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
[TBL] [Abstract][Full Text] [Related]
20. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.
Vermeulen J; De Preter K; Naranjo A; Vercruysse L; Van Roy N; Hellemans J; Swerts K; Bravo S; Scaruffi P; Tonini GP; De Bernardi B; Noguera R; Piqueras M; Cañete A; Castel V; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Michon J; Combaret V; Fischer M; Oberthuer A; Ambros PF; Beiske K; Bénard J; Marques B; Rubie H; Kohler J; Pötschger U; Ladenstein R; Hogarty MD; McGrady P; London WB; Laureys G; Speleman F; Vandesompele J
Lancet Oncol; 2009 Jul; 10(7):663-71. PubMed ID: 19515614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]